Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism - PubMed

Comment

Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism

Richard H White. Evid Based Med. 2008 Oct.

Comment on

• The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.

  Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. Douketis JD, et al. Ann Intern Med. 2007 Dec 4;147(11):766-74. doi: 10.7326/0003-4819-147-11-200712040-00007. Ann Intern Med. 2007. PMID: 18056660

Similar articles

• Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions.

  Douketis JD. Douketis JD. Curr Opin Pulm Med. 2008 Sep;14(5):381-8. doi: 10.1097/MCP.0b013e3283043dcf. Curr Opin Pulm Med. 2008. PMID: 18664966 Review.

• Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.

  Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Martinelli I, et al. Circulation. 2010 Jun 29;121(25):2740-6. doi: 10.1161/CIRCULATIONAHA.109.927046. Epub 2010 Jun 14. Circulation. 2010. PMID: 20547928

• Long-term incidence of death due to thromboembolic disease among patients with unprovoked pulmonary embolism.

  White RH, Murin S. White RH, et al. Curr Opin Pulm Med. 2009 Sep;15(5):418-24. doi: 10.1097/MCP.0b013e32832d044a. Curr Opin Pulm Med. 2009. PMID: 19458530 Review.

• A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

  Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. Kearon C, et al. N Engl J Med. 1999 Mar 25;340(12):901-7. doi: 10.1056/NEJM199903253401201. N Engl J Med. 1999. PMID: 10089183 Clinical Trial.

• The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

  Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E. Schulman S, et al. N Engl J Med. 1997 Feb 6;336(6):393-8. doi: 10.1056/NEJM199702063360601. N Engl J Med. 1997. PMID: 9010144 Clinical Trial.

Publication types

LinkOut - more resources

• Full Text Sources

  • HighWire
  • Ovid Technologies, Inc.